Targeted inhibition of FAK, PYK2 and BCL-XL synergistically enhances apoptosis in ovarian clear cell carcinoma cell lines

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Yoon, Heejei ^a   Choi, Yoon La ^a   Song, Ji Young ^a   Do, Ingu ^a   Kang, So Young ^a   Ko, Young Hyeh ^a   Song, Sangyong ^a   Kim, Byoung Gie ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; CASPASE 3; CASPASE 8; FOCAL ADHESION KINASE; FOCAL ADHESION KINASE 2; FOCAL ADHESION KINASE INHIBITOR; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PF 562 271; PF 573 228; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BCL XL; PROTEIN KINASE B; PROTEIN MCL 1; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL; CARCINOMA CELL; CELL DEATH; CELL PROLIFERATION; CLEAR CELL CARCINOMA; CONTROLLED STUDY; COPY NUMBER VARIATION; CYTOTOXICITY; DOWN REGULATION; DRUG MECHANISM; DRUG POTENTIATION; DRUG SENSITIVITY; ENZYME INHIBITION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; MUTATION; OVARIAN CLEAR CELL CARCINOMA; OVARY CARCINOMA; SIGNAL TRANSDUCTION;

ADENOCARCINOMA, CLEAR CELL; ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-X PROTEIN; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; FOCAL ADHESION KINASE 1; FOCAL ADHESION KINASE 2; GENE DOSAGE; HUMANS; MUTATION; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; OVARIAN NEOPLASMS; PHOSPHORYLATION;

EID: 84895519775     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0088587     Document Type: Article

References (40)

1. del Carmen MG, Birrer M, Schorge JO (2012) Clear cell carcinoma of the ovary: a review of the literature. Gynecol Oncol 126: 481-490.
2. Jones S, Wang TL, Shih Ie M, Mao TL, Nakayama K, et al. (2010) Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science 330: 228-231.
3. Wiegand KC, Shah SP, Al-Agha OM, Zhao Y, Tse K, et al. (2010) ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med 363: 1532-1543.
4. Sung CO, Choi CH, Ko Y-H, Ju H, Choi Y-L, et al. (2013) Integrative genome wide analysis reveals PTK2 gene as candidat target in a subset of ovarian clear cell adenocarcinoma. Cancer Genetics.
5. McLean GW, Carragher NO, Avizienyte E, Evans J, Brunton VG, et al. (2005) The role of focal-adhesion kinase in cancer - a new therapeutic opportunity. Nat Rev Cancer 5: 505-515. (Pubitemid 40942827)
6. Halder J, Landen CN Jr, Lutgendorf SK, Li Y, Jennings NB, et al. (2005) Focal adhesion kinase silencing augments docetaxel-mediated apoptosis in ovarian cancer cells. Clin Cancer Res 11: 8829-8836. (Pubitemid 43005935)
7. Schultze A, Fiedler W (2010) Therapeutic potential and limitations of new FAK inhibitors in the treatment of cancer. Expert Opin Investig Drugs 19: 777-788.
8. Xia H, Nho RS, Kahm J, Kleidon J, Henke CA (2004) Focal adhesion kinase is upstream of phosphatidylinositol 3-kinase/Akt in regulating fibroblast survival in response to contraction of type I collagen matrices via a beta 1 integrin viability signaling pathway. J Biol Chem 279: 33024-33034. (Pubitemid 39014762)
9. Zhong X, Rescorla FJ (2012) Cell surface adhesion molecules and adhesion-initiated signaling: understanding of anoikis resistance mechanisms and therapeutic opportunities. Cell Signal 24: 393-401.
10. Bouchard V, Harnois C, Demers MJ, Thibodeau S, Laquerre V, et al. (2008) B1 integrin/Fak/Src signaling in intestinal epithelial crypt cell survival: integration of complex regulatory mechanisms. Apoptosis 13: 531-542.
11. Golubovskaya V, Beviglia L, Xu LH, Earp HS 3rd, Craven R, et al. (2002) Dual inhibition of focal adhesion kinase and epidermal growth factor receptor pathways cooperatively induces death receptor-mediated apoptosis in human breast cancer cells. J Biol Chem 277: 38978-38987. (Pubitemid 35154764)
12. Guessous F, Yang Y, Johnson E, Marcinkiewicz L, Smith M, et al. (2012) Cooperation between c-Met and focal adhesion kinase family members in medulloblastoma and implications for therapy. Mol Cancer Ther 11: 288-297.
13. Golubovskaya VM, Gross S, Kaur AS, Wilson RI, Xu LH, et al. (2003) Simultaneous inhibition of focal adhesion kinase and SRC enhances detachment and apoptosis in colon cancer cell lines. Mol Cancer Res 1: 755-764. (Pubitemid 37025594)
14. Halder J, Kamat AA, Landen CN Jr, Han LY, Lutgendorf SK, et al. (2006) Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy. Clin Cancer Res 12: 4916-4924. (Pubitemid 44338579)
15. Smith CS, Golubovskaya VM, Peck E, Xu LH, Monia BP, et al. (2005) Effect of focal adhesion kinase (FAK) downregulation with FAK antisense oligonucleotides and 5-fluorouracil on the viability of melanoma cell lines. Melanoma Res 15: 357-362. (Pubitemid 41558945)
16. Litvak V, Tian D, Shaul YD, Lev S (2000) Targeting of PYK2 to focal adhesions as a cellular mechanism for convergence between integrins and G protein-coupled receptor signaling cascades. J Biol Chem 275: 32736-32746.
17. Williams J, Lucas PC, Griffith KA, Choi M, Fogoros S, et al. (2005) Expression of Bcl-xL in ovarian carcinoma is associated with chemoresistance and recurrent disease. Gynecol Oncol 96: 287-295. (Pubitemid 40127123)
18. Shigemasa K, Katoh O, Shiroyama Y, Mihara S, Mukai K, et al. (2002) Increased MCL-1 expression is associated with poor prognosis in ovarian carcinomas. Jpn J Cancer Res 93: 542-550. (Pubitemid 34752911)
19. Dodier P, Piche A (2006) Bcl-X(L) is functionally non-equivalent for the regulation of growth and survival in human ovarian cancer cells. Gynecol Oncol 100: 254-263. (Pubitemid 43075258)
20. Brotin E, Meryet-Figuiere M, Simonin K, Duval RE, Villedieu M, et al. (2010) Bcl-XL and MCL-1 constitute pertinent targets in ovarian carcinoma and their concomitant inhibition is sufficient to induce apoptosis. Int J Cancer 126: 885-895.
21. Yecies D, Carlson NE, Deng J, Letai A (2010) Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1. Blood 115: 3304-3313.
22. Konopleva M, Contractor R, Tsao T, Samudio I, Ruvolo PP, et al. (2006) Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 10: 375-388. (Pubitemid 44693472)
23. Chen S, Dai Y, Harada H, Dent P, Grant S (2007) Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation. Cancer Res 67: 782-791. (Pubitemid 46192219)
24. Wei G, Margolin AA, Haery L, Brown E, Cucolo L, et al. (2012) Chemical genomics identifies small-molecule MCL1 repressors and BCL-xL as a predictor of MCL1 dependency. Cancer Cell 21: 547-562.
25. Keuling AM, Felton KE, Parker AA, Akbari M, Andrew SE, et al. (2009) RNA silencing of Mcl-1 enhances ABT-737-mediated apoptosis in melanoma: role for a caspase-8-dependent pathway. PLoS One 4: e6651.
26. Slinker BK (1998) The statistics of synergism. J Mol Cell Cardiol 30: 723-731.
27. Slack-Davis JK, Martin KH, Tilghman RW, Iwanicki M, Ung EJ, et al. (2007) Cellular characterization of a novel focal adhesion kinase inhibitor. J Biol Chem 282: 14845-14852. (Pubitemid 47093369)
28. Roberts WG, Ung E, Whalen P, Cooper B, Hulford C, et al. (2008) Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271. Cancer Res 68: 1935-1944. (Pubitemid 351416580)
29. Inuzuka H, Shaik S, Onoyama I, Gao D, Tseng A, et al. (2011) SCF(FBW7) regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction. Nature 471: 104-109.
30. Rahmani M, Aust MM, Attkisson E, Williams DC Jr, Ferreira-Gonzalez A, et al. (2012) Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism. Cancer Res.
31. Boisvert-Adamo K, Longmate W, Abel EV, Aplin AE (2009) Mcl-1 is required for melanoma cell resistance to anoikis. Mol Cancer Res 7: 549-556.
32. Woods NT, Yamaguchi H, Lee FY, Bhalla KN, Wang HG (2007) Anoikis, initiated by Mcl-1 degradation and Bim induction, is deregulated during oncogenesis. Cancer Res 67: 10744-10752. (Pubitemid 350145901)
33. Nijhawan D, Fang M, Traer E, Zhong Q, Gao W, et al. (2003) Elimination of Mcl-1 is required for the initiation of apoptosis following ultraviolet irradiation. Genes Dev 17: 1475-1486. (Pubitemid 36734705)
34. Domina AM, Vrana JA, Gregory MA, Hann SR, Craig RW (2004) MCL1 is phosphorylated in the PEST region and stabilized upon ERK activation in viable cells, and at additional sites with cytotoxic okadaic acid or taxol. Oncogene 23: 5301-5315. (Pubitemid 39005806)
35. Maurer U, Charvet C, Wagman AS, Dejardin E, Green DR (2006) Glycogen synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1. Mol Cell 21: 749-760. (Pubitemid 43376126)
36. Chauhan D, Velankar M, Brahmandam M, Hideshima T, Podar K, et al. (2007) A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma. Oncogene 26: 2374-2380. (Pubitemid 46572819)
37. Okumura K, Huang S, Sinicrope FA (2008) Induction of Noxa sensitizes human colorectal cancer cells expressing Mcl-1 to the small-molecule Bcl-2/Bcl-xL inhibitor, ABT-737. Clin Cancer Res 14: 8132-8142.
38. Tamagiku Y, Sonoda Y, Kunisawa M, Ichikawa D, Murakami Y, et al. (2004) Down-regulation of procaspase-8 expression by focal adhesion kinase protects HL-60 cells from TRAIL-induced apoptosis. Biochem Biophys Res Commun 323: 445-452. (Pubitemid 39221118)
39. Xu LH, Yang X, Bradham CA, Brenner DA, Baldwin AS Jr, et al. (2000) The focal adhesion kinase suppresses transformation-associated, anchorage- independent apoptosis in human breast cancer cells. Involvement of death receptor-related signaling pathways. J Biol Chem 275: 30597-30604.
40. Kurenova E, Xu LH, Yang X, Baldwin AS Jr, Craven RJ, et al. (2004) Focal adhesion kinase suppresses apoptosis by binding to the death domain of receptor-interacting protein. Mol Cell Biol 24: 4361-4371. (Pubitemid 41071006)